---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-090766"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:05:40.847559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio announces Cell Reports publication showing XPro1595 promotes remyelination

## Summary
- Publication in Cell Reports demonstrates XPro1595 converts microglia from demyelinating to remyelinating cell.
- Study led by Hellenic Pasteur Institute; identifies solTNF as critical checkpoint for microglia polarization.
- Demyelination is core mechanism in neurodegeneration; XPro1595 targets solTNF to restore glia function.
- INmune expects top-line Phase II cognitive results in early Alzheimer's patients in first half of 2025.

## SEC filing metadata
- accession: 0001213900-24-090766
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/0001213900-24-090766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/ea0218672-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-090766
- JSON: https://secwatch.observer/filing/0001213900-24-090766.json
- Plain text: https://secwatch.observer/filing/0001213900-24-090766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.